-- 摩根士丹利週三在一份報告中指出，在即將上任的執行長西爾維奧·那不勒斯（Silvio Napoli）有時間評估公司業務及其前景之前，Lucid (LCID) 的股價預計將持續承壓。 報告顯示，該公司在經歷了「充滿挑戰」的第一季後，暫停了全年的交付量和資本支出指引。管理層報告稱，經調整後的息稅折舊攤提前利潤（EBITDA）虧損達7.81億美元。 摩根士丹利表示，預計虧損將持續高企，直至計劃於2027年推出的中型車。為了彌補虧損，Lucid已宣布從沙烏地阿拉伯公共投資基金、優步（UBER）以及註冊公開發行等管道籌集總計10.5億美元的資金。 摩根士丹利將2026年EBITDA預期下調了15%，原因是近期業績不佳導致毛利率下降，以及由於近期裁員支出導致營運費用增加。該公司也表示，預計全年交屋量仍為26,000輛，高於市場普遍預期的25,000輛。 摩根士丹利將該股的目標價從10美元下調至5美元，同時維持「減持」評級。
Price: $5.90, Change: $-0.35, Percent Change: -5.65%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%